TY - JOUR
T1 - Global hepatitis C elimination
T2 - an investment framework
AU - Pedrana, Alisa
AU - Howell, Jessica
AU - Scott, Nick
AU - Schroeder, Sophia
AU - Kuschel, Christian
AU - Lazarus, Jeffrey V.
AU - Atun, Rifat
AU - Baptista-Leite, Ricardo
AU - 't Hoen, Ellen
AU - Hutchinson, Sharon J.
AU - Aufegger, Lisa
AU - Peck, Raquel
AU - Sohn, Annette H.
AU - Swan, Tracy
AU - Thursz, Mark
AU - Lesi, Olufunmilayo
AU - Sharma, Manik
AU - Thwaites, John
AU - Wilson, David P.
AU - Hellard, Margaret
N1 - Funding Information:
We would like to acknowledge the contributions of Mary Ribeiro Pombo (Imperial College London), M Walid Qoronfleh (World Innovation Summit for Health, Qatar), Deidre Thompson (Imperial College London and World Innovation Summit for Health), Gottfried Hirnschall (former Director of Department of HIV and Global Hepatitis Programme, WHO), Yvan Hutin (strategic information at the Global Hepatitis Programme, WHO Eastern Mediterranean Regional Office) and the World Innovation Summit for Health 2018 Viral Hepatitis Forum. The authors gratefully acknowledge funding from the Qatar Foundation, the support to the Burnet Institute provided by the Victorian Government Operational Infrastructure Support Program, and the contributions of Campbell Aitkin (Burnet Institute, VIC, Australia) for his role in the review and editing of this manuscript. JVL is supported by a Spanish Ministry of Science, Innovation, and Universities Miguel Servet grant and further acknowledges support from the Spanish Ministry of Science, Innovation and Universities through the Centro de Excelencia Severo Ochoa 2019?2023 Programme (CEX2018-000806-S), and from the Government of Catalonia through the Centres de Recerca de Catalunya. AP, JH, and MH are the recipients of National Health and Medical Research Council fellowships.
Funding Information:
The Qatar Foundation provided funding for the World Innovations Summit for Health report, 2018, to the Burnet Institute. The funders had no role in the decision to publish or in the preparation of the manuscript. AP has received investigator-initiated research funding from Gilead Sciences, MSD, and AbbVie; and honoraria from Gilead Sciences, outside the submitted work. JVL reports grants and personal fees from AbbVie, Gilead Sciences, and MSD; and personal fees from CEPHEID, GSK, and Janssen, outside the submitted work. MH and the Burnet Institute receive investigator-initiated research funding from Gilead Sciences, AbbVie, and Bristol-Myers Squibb. NS receives investigator-initiated research funding from Gilead Sciences outside the submitted work. JH received the Gilead Sciences Australia fellowship (2017) and honoraria from Gilead Sciences. AHS reports institutional grants and travel funding from ViiV Healthcare and is the recipient of US NIH grants, outside the submitted work. E'tH is the former director of the Medicines Patent Pool. MS holds a research grant from the Qatar National Research Fund. SJH received honoraria from Gilead, outside the submitted work. All other authors declare no competing interests.
Funding Information:
We would like to acknowledge the contributions of Mary Ribeiro Pombo (Imperial College London), M Walid Qoronfleh (World Innovation Summit for Health, Qatar), Deidre Thompson (Imperial College London and World Innovation Summit for Health), Gottfried Hirnschall (former Director of Department of HIV and Global Hepatitis Programme, WHO), Yvan Hutin (strategic information at the Global Hepatitis Programme, WHO Eastern Mediterranean Regional Office) and the World Innovation Summit for Health 2018 Viral Hepatitis Forum. The authors gratefully acknowledge funding from the Qatar Foundation, the support to the Burnet Institute provided by the Victorian Government Operational Infrastructure Support Program, and the contributions of Campbell Aitkin (Burnet Institute, VIC, Australia) for his role in the review and editing of this manuscript. JVL is supported by a Spanish Ministry of Science, Innovation, and Universities Miguel Servet grant and further acknowledges support from the Spanish Ministry of Science, Innovation and Universities through the Centro de Excelencia Severo Ochoa 2019–2023 Programme (CEX2018-000806-S), and from the Government of Catalonia through the Centres de Recerca de Catalunya. AP, JH, and MH are the recipients of National Health and Medical Research Council fellowships.
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/10
Y1 - 2020/10
N2 - WHO has set global targets for the elimination of hepatitis B and hepatitis C as a public health threat by 2030. However, investment in elimination programmes remains low. To help drive political commitment and catalyse domestic and international financing, we have developed a global investment framework for the elimination of hepatitis B and hepatitis C. The global investment framework presented in this Health Policy paper outlines national and international activities that will enable reductions in hepatitis C incidence and mortality, and identifies potential sources of funding and tools to help countries build the economic case for investing in national elimination activities. The goal of this framework is to provide a way for countries, particularly those with minimal resources, to gain the substantial economic benefit and cost savings that come from investing in hepatitis C elimination.
AB - WHO has set global targets for the elimination of hepatitis B and hepatitis C as a public health threat by 2030. However, investment in elimination programmes remains low. To help drive political commitment and catalyse domestic and international financing, we have developed a global investment framework for the elimination of hepatitis B and hepatitis C. The global investment framework presented in this Health Policy paper outlines national and international activities that will enable reductions in hepatitis C incidence and mortality, and identifies potential sources of funding and tools to help countries build the economic case for investing in national elimination activities. The goal of this framework is to provide a way for countries, particularly those with minimal resources, to gain the substantial economic benefit and cost savings that come from investing in hepatitis C elimination.
UR - http://www.scopus.com/inward/record.url?scp=85089362398&partnerID=8YFLogxK
U2 - 10.1016/S2468-1253(20)30010-8
DO - 10.1016/S2468-1253(20)30010-8
M3 - Review Article
C2 - 32730786
AN - SCOPUS:85089362398
SN - 2468-1253
VL - 5
SP - 927
EP - 939
JO - The Lancet Gastroenterology & Hepatology
JF - The Lancet Gastroenterology & Hepatology
IS - 10
ER -
